Patients who have undergone previous treatments are more likely to develop the del(17p)/TP53 mutation, suggesting that CLL clones with del(17p) change during treatment. Clinical trials are recommended for the treatment of patients with this mutation. Alternatively, for individuals without substantial comorbidities who are refractory to small-molecule inhibitor therapy, allogeneic hematopoietic stem cell transplantation may be considered.
Learn more about recent advances in CLL.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Karl J. D'Silva. Fast Five Quiz: Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) - Medscape - Jun 23, 2020.
Comments